View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsUnity Biotechnology 과거 순이익 실적과거 기준 점검 0/6Unity Biotechnology은 연평균 27.6%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17.9%의 비율로 증가했습니다. 매출은 연평균 15.4%의 비율로 감소했습니다.핵심 정보27.62%순이익 성장률49.23%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률-15.35%자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Mar 2025최근 과거 실적 업데이트Unity Biotechnology, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2024Mar 08Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020Mar 25Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020Jul 25모든 업데이트 보기Recent updatesUnity Biotechnology, Inc. announced that it has received $0.000001 million in fundingJul 23Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from S&P TMI IndexJul 11Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from NASDAQ Composite IndexJul 09Nasdaq to Suspend Unity Biotechnology Common Stock At the Opening of Business on July 9, 2025, Due to Non-ComplianceJul 02Unity Biotechnology Receives Non-Compliance Notice from the Nasdaq Regarding Minimum Bid Price RequirementJun 23UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate UpdatesMay 06UNITY Biotechnology, Inc. Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DMEApr 24Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular EdemaMar 24UNITY Biotechnology, Inc. Receives A Non-Compliance Letter from the Nasdaq Stock MarketMar 18Unity Biotechnology, Inc. Appoints Dr. Yehia Hashad, M.D., as Member of the Science CommitteeMar 10Unity Biotechnology, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2024Mar 08New minor risk - Profitability Jan 12New major risk - Share price stability Jan 06UNITY Biotechnology Appoints Federico Grossi as Chief Medical OfficerJan 06Forecast to breakeven in 2027 Jan 01Insufficient new directors Dec 30New minor risk - Share price stability Nov 17UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy OfficerJul 22Insufficient new directors Jul 02Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024Apr 28Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DMEApr 24Unity Biotechnology, Inc. announced delayed annual 10-K filingApr 03Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision LossFeb 06Insufficient new directors Jan 01Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DMEDec 12New major risk - Financial position Nov 15UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular DegenerationSep 28New major risk - Revenue and earnings growth Sep 01Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)Jun 22Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular EdemaNov 02Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular DegenerationSep 20Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.Aug 18Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular EdemaAug 13Unity Biotechnology Receives Non-Compliance Notice from NasdaqJun 09UNITY Biotechnology Announces Board ChangesMay 27UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular DiseasesMay 06Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022May 02UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular DegeneraApr 20Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular EdemaApr 13Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, IncApr 03Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye DiseaseFeb 15Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022Jan 05Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E IndexJun 28+ 6 more updatesUNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye DiseasesMay 02Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020Mar 25Unity Biotechnology, Inc. Appoints Alexander Nguyen as General CounselMar 13Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye DiseasesFeb 09New 90-day high: €6.20 Feb 08Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific AdvisorFeb 02New 90-day high: €5.29 Jan 14Unity Biotechnology Announces Executive ChangesDec 15New 90-day high: €4.03 Nov 16Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular EdemaOct 13Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.Aug 06Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020Jul 25Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value IndexJul 02매출 및 비용 세부 내역Unity Biotechnology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:9U9 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 250-2816031 Dec 240-2615030 Sep 240-2215-630 Jun 240-3016-431 Mar 240-4018031 Dec 230-4019030 Sep 230-34191530 Jun 230-33201131 Mar 230-3119031 Dec 220-4420030 Sep 225-5621030 Jun 225-5922031 Mar 225-6423-931 Dec 215-6123030 Sep 210-7023-5430 Jun 210-8124-3531 Mar 210-8224-1131 Dec 200-9424030 Sep 200-922412530 Jun 200-862310631 Mar 200-91229031 Dec 190-8220030 Sep 190-8619030 Jun 190-8318031 Mar 190-7917031 Dec 180-76165930 Sep 181-6714030 Jun 181-6012031 Mar 181-5211031 Dec 171-45100양질의 수익: 9U9 은(는) 현재 수익성이 없습니다.이익 마진 증가: 9U9는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 9U9는 수익성이 없지만 지난 5년 동안 연평균 27.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 9U9의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 9U9은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(45%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 9U9의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/10/03 12:38종가2025/10/01 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Unity Biotechnology, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yigal NochomovitzCitigroup IncMatthew HarrisonMorgan StanleyDylan DupuisRoth Capital Partners1명의 분석가 더 보기
Unity Biotechnology, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2024Mar 08
Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020Mar 25
Nasdaq to Suspend Unity Biotechnology Common Stock At the Opening of Business on July 9, 2025, Due to Non-ComplianceJul 02
Unity Biotechnology Receives Non-Compliance Notice from the Nasdaq Regarding Minimum Bid Price RequirementJun 23
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate UpdatesMay 06
UNITY Biotechnology, Inc. Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DMEApr 24
Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular EdemaMar 24
Unity Biotechnology, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2024Mar 08
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DMEApr 24
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision LossFeb 06
UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular DegenerationSep 28
Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)Jun 22
Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular EdemaNov 02
Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular DegenerationSep 20
Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.Aug 18
Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular EdemaAug 13
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular DiseasesMay 06
UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular DegeneraApr 20
Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular EdemaApr 13
Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, IncApr 03
Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye DiseaseFeb 15
Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022Jan 05
UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye DiseasesMay 02
Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020Mar 25
Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye DiseasesFeb 09
Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular EdemaOct 13
Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.Aug 06